Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease

被引：78

作者：

Almradi, Ahmed ^{[1
,2
]}

Hanzel, Jurij ^{[2
]}

Sedano, Rocio ^{[1
,2
]}

Parker, Claire E. ^{[2
]}

Feagan, Brian G. ^{[1
,2
,5
]}

Ma, Christopher ^{[2
,3
,4
]}

Jairath, Vipul ^{[1
,2
,5
]}

机构：

[1] Western Univ, Dept Med, Div Gastroenterol, London, ON, Canada

[2] Alimentiv Inc, London, ON, Canada

[3] Univ Calgary, Dept Med, Div Gastroenterol & Hepatol, Calgary, AB, Canada

[4] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada

[5] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada

来源：

BIODRUGS | 2020年 / 34卷 / 06期

关键词：

GENOME-WIDE ASSOCIATION; SEVERE CROHNS-DISEASE; MAINTENANCE THERAPY; DOUBLE-BLIND; MODERATE; IL-23; RISANKIZUMAB; USTEKINUMAB; INDUCTION; ANTIBODY;

D O I：

10.1007/s40259-020-00451-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The inflammatory bowel diseases (IBDs) are chronic immune-mediated inflammatory disorders, including ulcerative colitis (UC) and Crohn's disease (CD). IBD results from a complex interplay between environmental, microbial, and genetic factors to create an abnormal immunological response leading to intestinal inflammation. Many pathways driving inflammation have been described, and different pathways may predominate in an individual patient. The interleukin (IL)-23 pathway plays a key role in IBD pathogenesis through promoting a pathological Th17 response. Targeting IL-23 is effective in the treatment of IBD. Ustekinumab, a monoclonal antibody targeting the shared p40 subunit of IL-12/23, is approved for treatment of moderate-to-severe CD and UC. Specific IL-23p19 antagonists are in development and promising results from phase II trials of mirikizumab and risankizumab underscore the potential for this class of treatment. In this review, we summarize the mechanisms of action and the evidence from clinical trials supporting the efficacy and safety of different IL-23 antagonists for IBD.

引用

页码：713 / 721

页数：9

共 36 条

[1] Safety, Tolerability, and Pharmacokinetics of PTG-200, an Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, in Normal Healthy Volunteers [J].

Cheng, Xiaoli ;

Lee, Tien-Yi ;

Ledet, Grace ;

Zemade, Genet ;

Tovera, James ;

Campbell, Robert ;

Purro, Nobert ;

Annamalai, Thamil ;

Masjedizadeh, Mohammad ;

Liu, David ;

Nawabi, Roya ;

Kanwar, Bittoo .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 :S439-S440

[2]

Cheng XL, 2017, INFLAMM BOWEL DIS, V23, pS88

[3] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study [J].

Deodhar, Atul ;

Gottlieb, Alice B. ;

Boehncke, Wolf-Henning ;

Dong, Bin ;

Wang, Yuhua ;

Zhuang, Yanli ;

Barchuk, William ;

Xu, Xie L. ;

Hsia, Elizabeth C. .

LANCET, 2018, 391 (10136) :2213-2224

[4] A genome-wide association study identifies IL23R as an inflammatory bowel disease gene [J].

Duerr, Richard H. ;

Taylor, Kent D. ;

Brant, Steven R. ;

Rioux, John D. ;

Silverberg, Mark S. ;

Daly, Mark J. ;

Steinhart, A. Hillary ;

Abraham, Clara ;

Regueiro, Miguel ;

Griffiths, Anne ;

Dassopoulos, Themistocles ;

Bitton, Alain ;

Yang, Huiying ;

Targan, Stephan ;

Datta, Lisa Wu ;

Kistner, Emily O. ;

Schumm, L. Philip ;

Lee, Annette T. ;

Gregersen, Peter K. ;

Barmada, M. Michael ;

Rotter, Jerome I. ;

Nicolae, Dan L. ;

Cho, Judy H. .

SCIENCE, 2006, 314 (5804) :1461-1463

[5] Interleukin-23: A key cytokine in inflammatory diseases [J].

Duvallet, Emilie ;

Semerano, Luca ;

Assier, Eric ;

Falgarone, Geraldine ;

Boissier, Marie-Christophe .

ANNALS OF MEDICINE, 2011, 43 (07) :503-511

[6] Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice [J].

Elson, Charles O. ;

Cong, Yingzi ;

Weaver, Casey T. ;

Schoeb, Trenton R. ;

McClanahan, Terrill K. ;

Fick, Robert B. ;

Kastelein, Robert A. .

GASTROENTEROLOGY, 2007, 132 (07) :2359-2370

[7] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease [J].

Feagan, B. G. ;

Sandborn, W. J. ;

Gasink, C. ;

Jacobstein, D. ;

Lang, Y. ;

Friedman, J. R. ;

Blank, M. A. ;

Johanns, J. ;

Gao, L. -L. ;

Miao, Y. ;

Adedokun, O. J. ;

Sands, B. E. ;

Hanauer, S. B. ;

Vermeire, S. ;

Targan, S. ;

Ghosh, S. ;

de Villiers, W. J. ;

Colombel, J. -F. ;

Tulassay, Z. ;

Seidler, U. ;

Salzberg, B. A. ;

Desreumaux, P. ;

Lee, S. D. ;

Loftus, E. V., Jr. ;

Dieleman, L. A. ;

Katz, S. ;

Rutgeerts, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1946-1960

[8] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study [J].

Feagan, Brian G. ;

Panes, Julian ;

Ferrante, Marc ;

Kaser, Arthur ;

D'Haens, Geert R. ;

Sandborn, William J. ;

Louis, Edouard ;

Neurath, Markus F. ;

Franchimont, Denis ;

Dewit, Olivier ;

Seidler, Ursula ;

Kim, Kyung-Jo ;

Selinger, Christian ;

Padula, Steven J. ;

Herichova, Ivona ;

Robinson, Anne M. ;

Wallace, Kori ;

Zhao, Jun ;

Minocha, Mukul ;

Othman, Ahmed A. ;

Soaita, Adina ;

Visvanathan, Sudha ;

Hall, David B. ;

Boecher, Wulf O. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10) :671-680

[9] Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study [J].

Feagan, Brian G. ;

Sandborn, William J. ;

D'Haens, Geert ;

Panes, Julian ;

Kaser, Arthur ;

Ferrante, Marc ;

Louis, Edouard ;

Franchimont, Denis ;

Dewit, Olivier ;

Seidler, Ursula ;

Kim, Kyung-Jo ;

Neurath, Markus F. ;

Schreiber, Stefan ;

Scholl, Paul ;

Pamulapati, Chandrasena ;

Lalovic, Bojan ;

Visvanathan, Sudha ;

Padula, Steven J. ;

Herichova, Ivona ;

Soaita, Adina ;

Hall, David B. ;

Bocher, Wulf O. .

LANCET, 2017, 389 (10080) :1699-1709

[10]

Ferrante M, 2020, J CROHNS COLITIS, V14, pS024

← 1 2 3 4 →